If PEAK (bezuclastinib + sunitinib) is approved, how would it influence your second-line treatment strategy for patients with advanced KIT-mutant GIST following imatinib failure?
1 Answers
Mednet Member
Medical Oncology · University of Miami Sylvester Comprehensive Cancer Center
